Perhaps future clinical trials investigating c-MET inhibitors and anti-HGF therapies in ovarian cancer should select for HGSC patients, given that the omenta in these patients produced significantly greater amounts of HGF compared to other subtypes and induced a robust cell migration response in HGSC. Here, MET is linked to ovarian cancer.